When the marrow itself is the problem, replacing it entirely can be the path to long-term remission.
Bone marrow transplant is one of the most intensive treatments in modern medicine — and one of the few that offers genuine curative potential for blood cancers and marrow failure syndromes. Thailand's JCI-accredited transplant centres handle allogeneic, autologous, and haploidentical procedures with experienced haematologists, dedicated isolation wards, and the round-the-clock monitoring these cases demand. The cost difference compared with the US or UK is significant enough to make this treatment accessible to patients who could not afford it at home.
Free, no-obligation — you pay the hospital directly with no markup.
Haematopoietic stem cell transplantation replaces bone marrow that has been destroyed by disease, high-dose chemotherapy, or radiation with healthy stem cells capable of regenerating your blood and immune system. It is a potentially curative treatment for acute and chronic leukaemias, lymphomas, myeloma, aplastic anaemia, and certain inherited blood disorders.
The transplant process involves several phases — pre-transplant evaluation, conditioning therapy, stem cell infusion, engraftment, and immune reconstitution. Each phase carries risks that require specialist management. Our partner hospitals have dedicated transplant units with HEPA-filtered isolation rooms, 24-hour haematology coverage, and blood banking infrastructure to support the entire process.
Transplant centres in the US and UK are expensive and often have waiting lists for non-urgent cases. Thailand provides the same quality of care with specialist teams who handle a high volume of transplants each year.
Specialist Units
Dedicated Transplant Wards
HEPA-filtered isolation rooms, 24-hour haematology nursing, on-site blood banking, and the infection-control infrastructure that transplant patients need during the engraftment period.
50–70%
Substantial Cost Savings
A bone marrow transplant in Thailand costs a fraction of the US or UK price. For a procedure totalling tens of thousands, the savings can make treatment financially possible.
Weeks
Faster Access to Treatment
Pre-transplant evaluation, donor workup, and conditioning can begin within weeks of referral. For time-sensitive haematological conditions, this acceleration matters clinically.
Global
International Patient Support
English-speaking haematology teams, dedicated coordinators, and experience managing international transplant patients through extended treatment stays of six to ten weeks.
We do not charge for our service — you pay the hospital directly with no markup. Here is what bone marrow transplant typically costs and how Thailand compares internationally.
Your Quote Will Include
Prices are approximate and vary by technique, surgeon, and hospital. Your personalised quote will include a full cost breakdown.
A bone marrow transplant in Thailand typically costs between $30,000 and $54,000. Autologous transplants sit at the lower end of the range, while allogeneic and haploidentical procedures cost more due to donor workup, longer isolation stays, GVHD management, and additional supportive care.
The haematologist's fee covers pre-transplant assessment, conditioning oversight, and post-transplant management. Hospital charges include the isolation ward, 24-hour nursing, and blood banking. Conditioning chemotherapy, stem cell processing, and supportive medications are itemised separately. Coordinator support is included throughout.
Transplant type is the main cost driver — autologous is simpler and shorter than allogeneic. Conditioning intensity affects toxicity management costs. Length of isolation stay, transfusion requirements, and complication management all influence the final total. Donor search fees for unrelated registry donors are additional.
Typical ranges at our partner hospitals:
Final pricing is confirmed after pre-transplant evaluation and treatment planning.
Bone marrow transplant in Thailand costs 50 to 70 percent less than equivalent procedures in the US ($90,000–$180,000), Australia (A$75,000–A$150,000), and UK (£66,000–£135,000). For a treatment that can exceed $100,000 privately, the difference makes transplant financially viable for many more patients.
The transplant type depends on the disease, its biology, and whether a suitable donor is available. Each carries a distinct risk-benefit profile that your haematologist discusses thoroughly before you consent.
Your own stem cells are collected from peripheral blood before high-dose conditioning, then reinfused to rescue marrow function. No graft-versus-host disease risk. The standard approach for myeloma and relapsed lymphoma, where the goal is to enable dose-intensive chemotherapy that would otherwise destroy the bone marrow permanently.
Donor stem cells from a matched sibling or unrelated registry donor replace your diseased marrow. The donor graft provides a new immune system with a graft-versus-tumour effect — donor immune cells that continue to attack residual cancer. This is the standard curative approach for acute leukaemias and marrow failure.
A half-matched family donor — parent, child, or sibling — provides stem cells when no fully matched donor exists. Post-transplant cyclophosphamide protocols have made this approach increasingly viable, expanding access for patients from ethnic backgrounds underrepresented in donor registries.
The transplant process involves conditioning, infusion, and engraftment — each phase requiring specific clinical expertise. Here is how our partner centres manage the technical aspects.
High-dose chemotherapy with or without total body irradiation destroys the existing bone marrow completely before transplant. This creates space for donor cells and eliminates residual disease. It is the most intensive conditioning approach and requires the longest engraftment period in isolation.
Lower-dose conditioning regimens suppress the immune system enough for engraftment without fully ablating the marrow. Relies more heavily on the graft-versus-tumour effect. Suitable for older patients or those with comorbidities who cannot tolerate full myeloablative therapy.
High-dose cyclophosphamide given on days three and four after transplant selectively eliminates rapidly dividing alloreactive T-cells that would cause graft-versus-host disease. This protocol has been transformative for haploidentical transplants, making half-matched family donors a viable option.
The engraftment phase begins as infused stem cells migrate to your marrow cavities and start producing new blood cells. You remain in a HEPA-filtered isolation room with daily blood counts, infection surveillance, and nutritional support. This is the highest-risk period for infection.
Blood counts begin recovering and you may move from isolation to a step-down ward. Your team watches closely for graft-versus-host disease, infection, and organ complications. Medications are adjusted frequently and gradual increases in physical activity are encouraged.
Outpatient reviews continue with regular blood work and medication adjustments. Immune function is still rebuilding, so infection precautions remain in place. Your haematologist manages any GVHD symptoms and begins tapering immunosuppression where clinically appropriate.
Immune reconstitution continues over the first year. Vaccinations are rescheduled, dietary restrictions ease, and activity levels increase. Bone marrow biopsies and blood tests monitor disease status to confirm sustained remission and guide your long-term care plan.
Most patients spend two to four weeks in a HEPA-filtered isolation room while blood counts are at their lowest. Strict hygiene protocols apply and visitors are limited. You transition to a step-down ward once neutrophil counts reach a safe level, though infection precautions continue.
Most patients are cleared to travel six to ten weeks after the transplant infusion, once engraftment is confirmed, immediate complications are resolved, and outpatient monitoring is stable. Your haematologist provides a fitness-to-travel assessment and detailed handover to your home medical team.
Full immune reconstitution takes six to twelve months. During this period you should avoid crowds, raw foods, and contact with unwell people. Vaccinations are readministered on a schedule. Your haematologist monitors for late effects including chronic GVHD, endocrine changes, and secondary malignancy risk.
Bone marrow transplant is a major procedure with significant risks. Understanding these risks is part of making an informed treatment decision with your haematologist.
Thorough pre-transplant assessment — cardiac, pulmonary, hepatic, and renal function tests alongside infectious disease screening — identifies risk factors early. Your haematologist discusses your individual risk profile and expected outcomes before you proceed.
Yes. Our partner hospitals hold JCI accreditation and operate dedicated transplant units with the infrastructure these procedures require — HEPA-filtered isolation, 24-hour haematology coverage, blood banking, and intensive care capability. Transplant outcomes at these centres are consistent with published international data.
GVHD prevention begins with donor matching and conditioning protocol selection. Post-transplant immunosuppression — including calcineurin inhibitors and, for haploidentical cases, cyclophosphamide — reduces incidence. When GVHD occurs, it is graded and treated with corticosteroids, additional immunosuppression, or targeted therapies as needed.
Primary graft failure — where donor cells do not engraft — occurs in a small percentage of cases and may require a second transplant or alternative treatment. Disease relapse after transplant is managed through donor lymphocyte infusions, immunotherapy, or other salvage approaches. Your haematologist plans for these contingencies from the outset.
Transplant outcomes depend on the specialist team and the infrastructure around them. Here is what our partner centres provide.
Our partner hospitals operate dedicated bone marrow transplant units within their haematology departments. Bumrungrad International and Bangkok Hospital have transplant programmes with HEPA-filtered isolation wards, on-site stem cell processing laboratories, blood banking services, and intensive care units equipped for transplant complications.
Our partner haematologists are board-certified with fellowship training in transplant medicine. Many completed advanced training at international transplant centres and bring that experience to managing the complex clinical decisions that arise during conditioning, engraftment, and long-term follow-up.
HEPA-filtered isolation rooms, on-site blood banking, and 24-hour haematology coverage are non-negotiable. Ask about annual transplant volume — centres performing a higher number of procedures each year tend to manage complications more effectively. Confirm the centre has experience with your specific transplant type.
Transplant success is measured by engraftment, disease remission, and long-term survival. Here is what outcomes typically look like.
Engraftment — when donor cells begin producing new blood cells — typically occurs within two to three weeks. Many patients with acute leukaemia achieve long-term remission rates of 50 to 70 percent after allogeneic transplant. Autologous transplant for myeloma extends progression-free survival by several years. Outcomes improve steadily with advances in conditioning, GVHD prevention, and supportive care.
Your haematologist discusses expected outcomes based on your disease type, stage, and transplant approach. Recovery milestones include neutrophil engraftment, platelet recovery, hospital discharge, and incremental immune reconstitution over months. Disease status is monitored through blood tests and bone marrow biopsies at defined intervals.
A transplant requires an extended stay. Planning ahead for logistics, accommodation, and companion support makes the experience more manageable.
Plan for six to ten weeks minimum. This covers pre-transplant evaluation, conditioning therapy, the transplant infusion, isolation during engraftment, step-down ward recovery, and initial outpatient follow-up before you are cleared to travel home. Some patients require longer stays depending on complications.
Your package covers the haematologist and transplant team, conditioning chemotherapy, stem cell infusion, isolation ward and nursing, pre-transplant diagnostics including HLA typing, post-transplant medications and blood products, and coordinator support. Donor search fees, accommodation, and flights are arranged separately.
We strongly encourage patients to bring a family member or companion for the duration of the stay. The emotional and practical support during isolation and recovery is invaluable. Your coordinator can help arrange nearby accommodation for your companion and facilitate hospital visiting within infection-control guidelines.
Everything you need to know before your treatment
Patient Care Director
Last reviewed: March 25, 2026
Medical disclaimer: Content on this site is provided for informational purposes and should not be treated as medical advice. Outcomes, timelines, and eligibility differ from person to person. Consult a qualified medical professional before making any decisions about surgery or treatment.
Speak with our care coordinators for a free, no-obligation consultation and personalised quote.
Speak to Our TeamTestimonials
Real experiences from patients who travelled to Thailand for treatment.
Free & No Obligation
Tell us what you're considering and we'll come back with surgeon options, pricing, and a clear plan.
Get in Touch
Tell us about the procedure you are considering and a member of our team will respond within one working day with personalised guidance.
Loading your quote form...
